Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Krystal Biotech Inc. (KRYS)

NASDAQ: KRYS · Biological Products, (No Diagnostic Substances) · Pittsburgh, PA

Our rating: Positive

Call changed from Neutral to Positive at $305.03, moderate conviction, November 3, 2026.

Breaks if: The positive call breaks if revenue growth decelerates below 15% year-over-year in two consecutive quarterly reports within the next twelve months — that would indicate the franchise is approaching its rare-disease ceiling faster than the 44.6× multiple assumes. The call moves toward Conviction if management discloses a second program entering late-stage development (Phase 3 or NDA-ready), establishing the gene therapy platform as a multi-asset franchise with a credible growth vector beyond the current lead product.

Key figures

Market value$9.2B
Revenue, last 12 months$470M
Net income, last 12 months$225M
Free cash flow, last 12 months$310M
Price to earnings40.7×
Free cash flow yield3.4%
Dividend yield0.0%
Operating margin48.4%
Return on equity17.5%
Beta to the S&P 5000.88
Volatility, annualized41.5%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$127M30.2%$2.05$90M
June 30, 2026$119M24.1%$1.79$71M
March 31, 2026$116M31.9%$1.83$73M
December 31, 2025$107M17.5%$1.70$75M
September 30, 2025$98M16.6%$2.66$38M
June 30, 2025$96M36.6%$1.29$51M
March 31, 2025$88M94.9%$1.20$25M
December 31, 2024$91M116.3%$1.53$52M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

18 ledger entries and 24 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.